Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
95
-
Total 13F shares, excl. options
-
31.7M
-
Shares change
-
+1.01M
-
Total reported value, excl. options
-
$639M
-
Value change
-
+$17.6M
-
Put/Call ratio
-
0.54
-
Number of buys
-
41
-
Number of sells
-
-47
-
Price
-
$20.13
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2018
121 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2018.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 95 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.7M shares
of 105M outstanding shares and own 30.31% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4.31M shares), JPMORGAN CHASE & CO (3.81M shares), BlackRock Inc. (3.21M shares), FRANKLIN RESOURCES INC (2.98M shares), Bank of New York Mellon Corp (2.54M shares), ArrowMark Colorado Holdings LLC (2.31M shares), Vanguard Group Inc (1.74M shares), ALLIANCEBERNSTEIN L.P. (1.56M shares), NovaQuest Capital Management, L.L.C. (1.56M shares), and Capital World Investors (1.23M shares).
This table shows the top 95 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.